benazepril

基本解釋

CLINIC CURATIVE EFFECT OBSERVATION OF PREVENTION AND TREATMENT OF BENAZEPRIL IN ESSENTIAL HYPERTENSION PATIENTS.
苯那普利防治原發(fā)性高血壓臨床療效觀察。
Objective:[WT5BZ]To compare the effect and safeness of benazepril and captopril in treatment of renal hypertension.
目的 :比較苯那普利與卡托普利治療腎性高血壓的降壓效應(yīng)與安全性。
The incidence rate of adverse effect in irbesartan group was 12. 5%, and benazepril group 22.58%.
不良反應(yīng)發(fā)生率國(guó)產(chǎn)伊貝沙坦組為12.;5%25，苯那普利組為22
Aim.. To compare the reverse effect of Captopril with Benazepril on hypertensive left ventricular hypertrophy.
目的探討卡托普利與苯那普利治療高血壓及逆轉(zhuǎn)左室肥厚的作用。
RESULTS:The ADR induced by benazepril was associated with the aggregation of bradykinin in vivo.
結(jié)果:貝那普利所致不良反應(yīng)主要表現(xiàn)為咳嗽、皮膚過敏反應(yīng)等,其與體內(nèi)緩激肽的聚集有關(guān)。

貝那普利
Conclusion: Benazepril has a good therapeutic efficacy on chronic pneumocardial disease with cardiac failure.
結(jié)論：貝那普利對(duì)慢性肺心病心力衰竭有良好的治療效果。
苯那普利
Results Serum total cholesterol were effectively decreased in 3 groups after therapy. Combination of benazepril and valsartan therapy reduced triglyceride effectively.
結(jié)果治療后各組血清總膽固醇水平顯著降低;聯(lián)合治療組甘油三酯水平顯著降低（P苯那普利組和聯(lián)合治療組對(duì)低密度脂蛋白、載脂蛋白B水平的影響大于纈沙坦組（P
苯拉普利
Objective: To explore the effect of Benazepril on the levels ofMMP-9 and CRP in patients with ACS.
目的：探討苯拉普利對(duì)ACS患者血清MMP-9及CRP水平的影響。